GlassScriptPhysician profile
Tittymol Mathew
NPI 1114950565
$1,378.86
in general payments reported to CMS, 2019-2025
27 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $42.45 · 2021: $117 · 2022: $164 · 2023: $256 · 2024: $138 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $267.95 | 2021-2025 | |
| Davol INC. | $150.00 | 2025 | Phasix Mesh |
| Lilly USA, LLC | $113.43 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $110.59 | 2019-2024 | Farxiga, Breztri, Fasenra |
| Novo Nordisk INC | $109.22 | 2019-2023 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $80.09 | 2019-2021 | |
| Exact Sciences Corporation | $66.82 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $41.55 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.55 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $40.68 | 2019-2022 | |
| Glaxosmithkline, LLC. | $35.51 | 2019 | |
| Idorsia Pharmaceuticals US INC | $31.65 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $29.80 | 2022-2023 | |
| Amgen INC. | $25.35 | 2022 | |
| Paratek Pharmaceuticals, INC. | $24.99 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.85 | 2019 | |
| Allergan, INC. | $22.47 | 2019 | |
| Snap Diagnostics LLC | $20.52 | 2023 | Snap Diagnostics Study |
| Boston Scientific Corporation | $20.00 | 2019 | |
| Abbott Laboratories | $19.48 | 2022 | |
| Philips North America LLC | $18.60 | 2021 | |
| Corcept Therapeutics | $17.19 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $14.48 | 2024 | |
| Mylan Specialty L.P. | $14.17 | 2019 | |
| Astellas Pharma US INC | $13.70 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.50 | 2023 | Crysvita |
| Nabriva Therapeutics, Plc | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tittymol Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.